Company Filing History:
Years Active: 2023-2025
Title: The Innovations of Ryan P. Larson: Pioneering Cell Therapy
Introduction
Ryan P. Larson is an innovative inventor based in Seattle, WA, recognized for his contributions to the field of cell therapy. With a total of four patents to his name, Larson has made significant strides in improving the efficacy and safety of therapeutics involving T cells.
Latest Patents
Larson's most recent patents focus on two groundbreaking areas in CAR T-cell therapy. The first patent, titled "Determining Toxicity Risk in CAR T-cell Therapy," provides methods, compositions, and articles for enhancing the safety of therapeutic T cell compositions. By administering specific doses of these T cell compositions, which express recombinant receptors like chimeric antigen receptors (CARs), the patent aims to minimize toxicity risks in subjects.
Additionally, his patent on "Phenotypic Markers for Cell Therapy and Related Methods" outlines methods and compositions that can improve dosing consistency while reducing the risk of toxicity and increasing therapeutic responses from T cell compositions. Both patents highlight Larson's commitment to advancing cell therapy and making it safer for patients.
Career Highlights
Ryan P. Larson is currently associated with Juno Therapeutics GmbH, a company specializing in pioneering cell therapies. His role has allowed him to leverage his innovative ideas into practical applications that have the potential to transform clinical practices in oncology and immunotherapy.
Collaborations
Throughout his career, Larson has collaborated with notable colleagues, including Christopher Glen Ramsborg and Nathan Yee. These partnerships reflect a strong collaborative spirit that drives innovation in the field of therapeutics, emphasizing the importance of teamwork in scientific advancements.
Conclusion
In conclusion, Ryan P. Larson stands out as a leading inventor in the realm of CAR T-cell therapy. His patents demonstrate a clear vision towards enhancing the safety and effectiveness of cell therapies. With his continued work at Juno Therapeutics GmbH and through collaborations with industry peers, Larson is poised to further impact the world of medical innovations, benefiting patients and the healthcare community alike.